Consensus Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.24 USD -1.59% Intraday chart for Aclaris Therapeutics, Inc. +3.33% +18.10%

Evolution of the average Target Price on Aclaris Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

96f7b026257bb.zLluNi6QetsKX5XpUx_464W5V2D9AeESkV-oeqLzjlI.oe87ZXn-N55OFN2kFFebjMPDNg-VdJZH8BbiP-O3zwiLziJfd9tImlARrQ~180e6436fd1939de9f005a91e49b0017
HC Wainwright Downgrades Aclaris Therapeutics to Neutral From Buy MT
BTIG Downgrades Aclaris Therapeutics to Neutral From Buy MT
Stifel Trims Price Target on Aclaris Therapeutics to $1 From $2, Maintains Hold Rating MT
HC Wainwright Cuts Price Target on Aclaris Therapeutics to $9 From $43, Maintains Buy Rating MT
Cantor Fitzgerald Downgrades Aclaris Therapeutics to Neutral From Overweight MT
Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating MT
Piper Sandler Downgrades Aclaris Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $30 MT
Stifel Downgrades Aclaris Therapeutics to Hold From Buy, Cuts Price Target to $2 From $20 MT
William Blair Downgrades Aclaris Therapeutics to Market Perform From Outperform MT
Evercore ISI Initiates Aclaris Therapeutics at Outperform Rating With $22 Price Target MT
Stifel Adjusts Price Target on Aclaris Therapeutics to $20 From $16, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Aclaris Therapeutics to $21 From $25, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $43 From $50, Maintains Buy Rating MT
BTIG Research Adjusts Aclaris Therapeutics Price Target to $29 From $32, Maintains Buy Rating MT
Stifel Nicolaus Initiates Coverage on Aclaris Therapeutics With Buy Rating, $29 Price Target MT
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target MT
BTIG Starts Aclaris Therapeutics at Buy With $32 Price Target MT
ACLARIS THERAPEUTICS : HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $50 From $40, Reiterates Buy Rating MT
ACLARIS THERAPEUTICS : Piper Sandler Starts Aclaris Therapeutics at Overweight With $30 Price Target MT
ACLARIS THERAPEUTICS : HC Wainwright Initiates Aclaris Therapeutics at Buy Rating With $40 Price Target MT
ACLARIS THERAPEUTICS : SVB Leerink Adjusts Price Target on Aclaris Therapeutics to $26 From $21, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
1.24 USD
Average target price
1.8 USD
Spread / Average Target
+45.16%
High Price Target
3 USD
Spread / Highest target
+141.94%
Low Price Target
1 USD
Spread / Lowest Target
-19.35%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Aclaris Therapeutics, Inc.

HC Wainwright
BTIG
Stifel Nicolaus
Cantor Fitzgerald
Evercore ISI
William Blair & Co.
Piper Sandler
Goldman Sachs
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings